It sure is nice to have multiple shots on goal.
Regeneron didn't even bother to issue a press release about it or hold a conference call to discuss the ramifications; it just filed a short 8-K with the Securities and Exchange Commission to let shareholders know the bad news. Investors shrugged it off in kind. Shares are essentially flat today.
It's not that REGN475/SAR164877 doesn't work; the drug passed a phase 2 trial testing it in patients with osteoarthritis of the knee. But Regeneron has a bunch of other drugs that are farther along, which make up a majority of its value.
For instance, VEGF Trap-Eye looks like it'll have a fairly easy time getting past the FDA now that the company has announced two positive phase 3 trials. Regeneron also has two other phase 3 compounds: cancer drug aflibercept and its already-approved Arcalyst, which is being tested as a treatment for gout. And there's Regeneron's deal with Sanofi to develop four to five new drugs per year through 2017. The company can certainly afford to lose a phase 2 pipeline candidate.
The clinical hold might actually affect Pfizer
If the class was going to die, being late to the party like Sanofi, Regeneron, and Johnson & Johnson
Interested in keeping track of Regeneron as it develops its extensive pipeline? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Regeneron.